ATE407701T1 - Wässrige proteinformulierung mit verzögerter freigabe - Google Patents

Wässrige proteinformulierung mit verzögerter freigabe

Info

Publication number
ATE407701T1
ATE407701T1 AT02780626T AT02780626T ATE407701T1 AT E407701 T1 ATE407701 T1 AT E407701T1 AT 02780626 T AT02780626 T AT 02780626T AT 02780626 T AT02780626 T AT 02780626T AT E407701 T1 ATE407701 T1 AT E407701T1
Authority
AT
Austria
Prior art keywords
delayed release
protein formulation
release protein
aqueous delayed
aqueous
Prior art date
Application number
AT02780626T
Other languages
English (en)
Inventor
Basant Sharma
Renzhe Jin
Sunitha Rudolph
Wing Cheung
Selima Begum
Marian Kelley
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Application granted granted Critical
Publication of ATE407701T1 publication Critical patent/ATE407701T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT02780626T 2001-11-07 2002-10-25 Wässrige proteinformulierung mit verzögerter freigabe ATE407701T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/037,369 US6818613B2 (en) 2001-11-07 2001-11-07 Aqueous sustained-release formulations of proteins

Publications (1)

Publication Number Publication Date
ATE407701T1 true ATE407701T1 (de) 2008-09-15

Family

ID=21893975

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02780626T ATE407701T1 (de) 2001-11-07 2002-10-25 Wässrige proteinformulierung mit verzögerter freigabe

Country Status (20)

Country Link
US (3) US6818613B2 (de)
EP (1) EP1441771B1 (de)
JP (1) JP2005514394A (de)
CN (1) CN1612752A (de)
AR (1) AR037260A1 (de)
AT (1) ATE407701T1 (de)
AU (1) AU2002343666B2 (de)
BR (1) BR0213992A (de)
CA (1) CA2465890A1 (de)
CY (1) CY1110271T1 (de)
DE (1) DE60228864D1 (de)
DK (1) DK1441771T3 (de)
ES (1) ES2312633T3 (de)
HK (1) HK1066468A1 (de)
MX (1) MXPA04004367A (de)
MY (1) MY136952A (de)
PT (1) PT1441771E (de)
SI (1) SI1441771T1 (de)
TW (1) TWI332845B (de)
WO (1) WO2003053471A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311285E (pt) * 2000-05-15 2005-06-30 Hoffmann La Roche Composicao farmaceutica liquida contendo um derivado de eritropoietina
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
DE602004013557D1 (de) * 2003-02-28 2008-06-19 Ares Trading Sa FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1537876A1 (de) * 2003-12-01 2005-06-08 BioGeneriX AG Formulierung einer Erythropoietin Lösung
EP1720564A1 (de) * 2004-02-20 2006-11-15 Rinat Neuroscience Corp. Verfahren zur behandlung von fettsucht oder diabetes mit nt-4/5
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
KR101150242B1 (ko) 2004-10-27 2012-06-13 유니버시티 오브 덴버 부신피질 자극 호르몬 유사체 및 관련 방법
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
TW200808352A (en) * 2006-02-02 2008-02-16 Rinat Neuroscience Corp Methods for treating unwanted weight loss or eating disorders by administering a TRKB agonist
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
WO2008121301A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human il-12 antibodies
JP2010528647A (ja) 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
AU2008261212A1 (en) * 2007-06-15 2008-12-18 University Of Zurich Treatment for Alzheimer' s disease
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
BRPI0821814A2 (pt) * 2007-12-28 2015-06-16 Heraeus Kulzer Gmbh Uso e formulação tópica de eritropoietina para a cicatrização da pele
US8357179B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US20110009941A1 (en) * 2009-07-08 2011-01-13 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8529596B2 (en) 2009-07-08 2013-09-10 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8795317B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Embolic obstruction retrieval devices and methods
US8795345B2 (en) * 2009-07-08 2014-08-05 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
US8357178B2 (en) * 2009-07-08 2013-01-22 Concentric Medical, Inc. Vascular and bodily duct treatment devices and methods
PT2637690T (pt) 2010-11-11 2016-12-27 Abbvie Biotechnology Ltd Formulações líquidas de anticorpo anti-tnf-alfa de concentração elevada
RU2599592C2 (ru) 2011-02-04 2016-10-10 Концентрик Медикал, Инк. Устройство для извлечения эмболической окклюзии
DK2726090T3 (da) 2011-07-01 2020-01-20 Biogen Ma Inc Argininfri tnfr: fc-fusionspolypeptidsammensætninger
TW201842929A (zh) * 2017-05-03 2018-12-16 美商必治妥美雅史谷比公司 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
EP0062827B1 (de) * 1978-06-16 1986-07-23 Kyowa Hakko Kogyo Co., Ltd Benzamidderivate
EP0090837A1 (de) 1981-10-08 1983-10-12 BERG, Kurt Frimann Verfahren und zusammensetzung zum behandeln von kranken die an interferon empfindlichen krankheiten leiden
JPH0686480B2 (ja) * 1983-02-21 1994-11-02 雪印乳業株式会社 エリスロポエチン製造用モノクローナル抗体
ES520813A0 (es) * 1983-03-21 1984-05-16 Prodes Sa Procedimiento para la obtencion del ester del acido 2-(2,6-diclorofenil)amino bencenoacetico con acido glicolico.
JPS604186A (ja) * 1983-06-21 1985-01-10 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン化合物
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4717717A (en) 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
CA2223583A1 (en) * 1995-06-07 1996-12-19 Alkermes Controlled Therapeutics Inc. Device for releasing aggregation-stabilized, biologically active agent
US5916597A (en) 1995-08-31 1999-06-29 Alkermes Controlled Therapeutics, Inc. Composition and method using solid-phase particles for sustained in vivo release of a biologically active agent
CN1215340A (zh) 1996-02-09 1999-04-28 安姆根有限公司 包含白介素－1抑制剂和控释聚合物的组合物
ATE341344T1 (de) 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
AU754619B2 (en) 1997-07-23 2002-11-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
DK0902085T3 (da) 1997-09-01 2004-04-05 Aventis Pharma Gmbh Rekombinant human erythropoietin med fordelagtig glycosyleringsprofil
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6548653B1 (en) 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
PT1107791E (pt) 1998-09-04 2007-07-06 Scios Inc Composições de hidrogel para a administração com libertação controlada de factores de crescimento
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
CO5160256A1 (es) 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
MXPA01010208A (es) 1999-04-09 2003-07-21 Johnson & Johnson Composiciones farmaceuticas de eritropoyetina.
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US6818613B2 (en) * 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins

Also Published As

Publication number Publication date
AU2002343666B2 (en) 2007-04-05
MY136952A (en) 2008-12-31
US20030181361A1 (en) 2003-09-25
US20030148938A1 (en) 2003-08-07
EP1441771A1 (de) 2004-08-04
EP1441771B1 (de) 2008-09-10
DE60228864D1 (de) 2008-10-23
CN1612752A (zh) 2005-05-04
US20050164927A1 (en) 2005-07-28
AU2002343666A1 (en) 2003-07-09
TW200303215A (en) 2003-09-01
PT1441771E (pt) 2008-10-29
TWI332845B (en) 2010-11-11
JP2005514394A (ja) 2005-05-19
DK1441771T3 (da) 2009-01-05
HK1066468A1 (en) 2005-03-24
BR0213992A (pt) 2004-08-31
AR037260A1 (es) 2004-11-03
CA2465890A1 (en) 2003-07-03
US7282480B2 (en) 2007-10-16
US6818613B2 (en) 2004-11-16
ES2312633T3 (es) 2009-03-01
CY1110271T1 (el) 2015-01-14
WO2003053471A1 (en) 2003-07-03
SI1441771T1 (sl) 2009-02-28
MXPA04004367A (es) 2005-05-16

Similar Documents

Publication Publication Date Title
ATE407701T1 (de) Wässrige proteinformulierung mit verzögerter freigabe
ATE506064T1 (de) Analgetika mit verzögerter wirkstoffabgabe
NO20033143L (no) Farmasoytisk preparat
DE60219383D1 (de) Wässrige Beschichtungszusammensetzung
CY2014009I1 (el) Παρασιτοκτονα σκευασματα
ATE495731T1 (de) Amphetaminsalz-formulierung mit verzögerter wirkstofffreigabe
NO20034026D0 (no) Nytt preparat
DE50202890D1 (de) Anhängekupplung
DE60011149D1 (de) Klare wässrige anästhesierende zusammensetzung
NO20034695L (no) Nytt preparat
DE60229399D1 (de) Hgf-hydrogel-zubereitungen mit verzögerter freisetzung
NO20025805L (no) Farmasöytisk preparat
DE60103683D1 (de) Wässrige Pestizidzusammensetzung
DE60234592D1 (de) Wässrige zusammensetzung
DK1361791T3 (da) Agrokemisk formulering
NO20033829D0 (no) Antiviralt preparat
BR0113783B1 (pt) Composição aquosa
NO20023392L (no) Preparat
FR2821754B1 (fr) Descenceur autobloquant
NO20026215D0 (no) Nytt hormonpreparat
ATA2892002A (de) Beschlag
DE10293967D2 (de) Verbindungsbeschlag
DE60223695D1 (de) Aminosäure-modulierte dosierform mit verlängerter freisetzung
NO20040250L (no) Metyl-tieno-benzodiazepinlyofilisert formulering
DE60237589D1 (de) Fusionsproteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441771

Country of ref document: EP